Overview

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
Phase:
Phase 1
Details
Lead Sponsor:
PharmaMar
Treatments:
Albumin-Bound Paclitaxel
Bevacizumab
Paclitaxel